DJIA 18,030.21 0.00 0.00%
NASDAQ 4,773.47 0.00 0.00%
S&P 500 2,081.88 0.00 0.00%
market minute promo

AstraZeneca plc (ADR) (NYSE: AZN)

70.44 0.00 (0.00%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

AZN $70.44 0.00%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $70.47
Previous Close $70.44
Daily Range $70.39 - $71.05
52-Week Range $58.29 - $82.68
Market Cap $89.0B
P/E Ratio 34.40
Dividend (Yield) $1.80 (4.0%)
Ex-Dividend Date
Dividend Pay Date
08/13/14
09/15/14
Volume 814,807
Average Daily Volume 1,776,748
Current FY EPS $4.41

Sector

Healthcare

Industry

Drugs

AstraZeneca plc (ADR) (AZN) Description

The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation. Website: http://www.astrazeneca.com/

News & Commentary Rss Feed

3 Drugmakers Facing a Pivotal 2015

Isis Pharmaceuticals, PTC Therapeutics, and GW Pharmaceuticals all expect 2015 to be a pivotal year in their drive toward becoming commercially viable entities. Should investors jump in before the catalysts spark?

Update: Myriad Genetics Won FDA Approval For BRACAnalysis CDx

Myriad Genetics' Ovarian Cancer Test Wins FDA Approval - Analyst Blog

Myriad Genetics' Ovarian Cancer Test Wins FDA Approval - Analyst Blog

European ADRs Lifted by Pharmaceutical Stock Gains

The Global Defenders

European ADRs Lower on Pharmaceutical Stock Contraction

AstraZeneca's Lynparza Cleared in U.S. for Ovarian Cancer - Analyst Blog

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?

The Most Disappointing Clinical Failures in 2014

Three Motley Fool contributors tell us what they think were the biggest drug trial failures this year.

Update: In A Surprise Twist, AstraZeneca Wins Accelerated FDA Approval For Lynparza

See More AZN News...

AZN's Top Competitors

AZN $70.44 (0.00%)
Current stock: AZN
JNJ $104.59 (0.00%)
Current stock: JNJ
NVS $93.91 (0.00%)
Current stock: NVS
RHHBY $34.28 (0.00%)
Current stock: RHHBY